MorphoSys (MOR.DE) Stock Price
MorphoSys Price
MorphoSys (MOR.DE) Stock | ISIN DE0006632003 | WKN 663200. Revenue is 449.11 M EUR. Net income is -40.89 M EUR. MorphoSys operates in the Health sector.
MorphoSys stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of MorphoSys over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MorphoSys stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MorphoSys's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | MorphoSys Price |
|---|
MorphoSys Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
MorphoSys Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M EUR) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M EUR) |
| NET INCOME (M EUR) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales MorphoSys generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MorphoSys retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MorphoSys's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares MorphoSys has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MorphoSys's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
MorphoSys stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
MorphoSys Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
MorphoSys business model & stock analysis
MorphoSys SWOT Analysis
Strengths
MorphoSys AG possesses several key strengths that contribute to its competitive advantage in the industry. Firstly, the company has a strong portfolio of innovative and proprietary technologies, such as its antibody and protein engineering platform, which enables the discovery and development of novel therapeutic antibodies. This technology leadership allows MorphoSys to differentiate itself from competitors and attract collaborations and partnerships.
Secondly, MorphoSys has established a robust pipeline of drug candidates across various therapeutic areas, including oncology, immunology, and inflammation. This diversified portfolio minimizes the company's dependency on a single product and provides opportunities for growth and revenue diversification.
Additionally, the company benefits from strong intellectual property rights and a solid track record in obtaining and defending its patents. This provides MorphoSys with a strong barrier to entry and protection against potential competitors.
Weaknesses
Despite its strengths, MorphoSys AG also faces certain weaknesses. One of the primary concerns is the company's heavy reliance on collaborations and partnerships for the development and commercialization of its drug candidates. This leaves MorphoSys vulnerable to potential delays or disruptions in these collaborations, which could impact its pipeline and revenue streams.
Furthermore, the company's financial performance has been inconsistent, with fluctuations in revenue and profitability over the years. This can be attributed to the high costs associated with research and development activities, as well as the uncertainty surrounding the success and market acceptance of its drug candidates.
Opportunities
MorphoSys AG operates in a rapidly evolving and growing biopharmaceutical industry, which presents several opportunities for the company. The increasing prevalence of complex diseases, such as cancer and autoimmune disorders, offers a significant market potential for innovative therapeutic solutions developed by MorphoSys.
Moreover, advancements in technology and scientific understanding provide opportunities for the company to expand its capabilities and develop novel treatment approaches. This includes areas like personalized medicine and immuno-oncology, where MorphoSys can leverage its expertise in antibody engineering to develop targeted and more effective therapies.
Threats
In addition to opportunities, MorphoSys AG also faces certain threats in the industry. One of the primary threats is the intense competition from both large pharmaceutical companies and emerging biotechnology firms. This competition can result in pricing pressure, limited market access, and the potential for rivals to develop similar or superior therapies.
Furthermore, regulatory uncertainties and challenges in obtaining approvals for new drugs pose a significant threat to MorphoSys. Compliance with stringent regulations and the risk of delays or rejections by regulatory bodies can impact the company's ability to bring its products to market in a timely manner.
MorphoSys Segments
MorphoSys Revenue by Region
3 Years
Max
Details
MorphoSys Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
MorphoSys historical P/E ratio, EBIT multiple, and P/S ratio
MorphoSys annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
MorphoSys shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
MorphoSys Earnings Estimates
MorphoSys Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 11/16/2022 | -1.53EUR | 68.52 MEUR | 2022 Q3 |
| 8/3/2022 | -1.94EUR | 58.82 MEUR | 2022 Q2 |
| 5/4/2022 | -1.87EUR | 47.3 MEUR | 2022 Q1 |
| 3/16/2022 | -2.79EUR | 47.11 MEUR | 2021 Q4 |
| 11/10/2021 | -2.58EUR | 39.53 MEUR | 2021 Q3 |
| 7/28/2021 | -1.95EUR | 35.07 MEUR | 2021 Q2 |
| 5/5/2021 | -1.39EUR | 46.22 MEUR | 2021 Q1 |
| 3/15/2021 | -2.16EUR | 33.98 MEUR | 2020 Q4 |
| 11/11/2020 | -1.87EUR | 19.56 MEUR | 2020 Q3 |
| 8/5/2020 | -1.57EUR | 10.73 MEUR | 2020 Q2 |
EESG©
Eulerpool ESG Scorecard© for the MorphoSys stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
MorphoSys shareholder structure
| % | Name |
|---|---|
109.91972% | |
0.30966% | |
0.17486% | |
0.12532% | |
0.1224% | |
0.10408% | |
0.09035% | |
0.06412% | |
0.0318% | |
0.03059% |
MorphoSys Executives and Management Board
Dr. Jean-Paul Kress
(58)Chairman of the Management Board, Chief Executive Officer
Dr. Marc Cluzel
(67)Independent Chairman of the Supervisory Board · since 2012
Dr. George Golumbeski
(65)Independent Deputy Chairman Member of the Supervisory Board · since 2018
Mr. Michael Brosnan
(68)Independent Member of the Supervisory Board
Mrs. Krisja Vermeylen
(61)Independent Member of the Supervisory Board
MorphoSys Supply Chain
Frequently asked questions about MorphoSys
MorphoSys AG operates under a differentiated business model in the biopharmaceutical industry. The company specializes in developing novel therapeutic antibodies to address unmet medical needs. Leveraging its proprietary technology, MorphoSys AG focuses on discovering and optimizing antibodies at an early stage, enabling the development of potential treatments for various diseases, including cancer and autoimmune disorders. By collaborating with pharmaceutical partners and licensing its innovative antibodies, MorphoSys AG generates revenue through upfront payments, milestone-related royalties, and product sales. This business model helps the company capitalize on its expertise in antibody development and create value through its diverse portfolio of potential therapies.
MorphoSys stock
MorphoSys Peer Group
MorphoSys Ticker
MorphoSys FIGI
All fundamentals and in-depth analysis of MorphoSys
Our stock analysis for MorphoSys Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MorphoSys Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.